Synthetic cannabinoid intake is an ongoing health issue worldwide, with new compounds continually emerging, making drug testing complex. Parent synthetic cannabinoids are rarely detected in urine, the most common matrix employed in workplace drug testing. Optimal identification of synthetic cannabinoid markers in authentic urine specimens and correlation of metabolite concentrations and toxicities would improve synthetic cannabinoid result interpretation. We screened 20 017 randomly collected US military urine specimens between July 2011 and June 2012 with a synthetic cannabinoid immunoassay yielding 1432 presumptive positive specimens. We analyzed all presumptive positive and 1069 negative specimens with our qualitative synthetic cannabinoid liquid chromatography-tandem mass spectrometry (LC-MS/MS) method, which confirmed 290 positive specimens. All 290 positive and 487 randomly selected negative specimens were quantified with the most comprehensive urine quantitative LC-MS/MS method published to date; 290 specimens confirmed positive for 22 metabolites from 11 parent synthetic cannabinoids. The five most predominant metabolites were JWH-018 pentanoic acid (93%), JWH-N-hydroxypentyl (84%), AM2201 N-hydroxypentyl (69%), JWH-073 butanoic acid (69%), and JWH-122 N-hydroxypentyl (45%) with 11.1 (0.1-2,434), 5.1 (0.1-1,239), 2.0 (0.1-321), 1.1 (0.1-48.6), and 1.1 (0.1-250) μg/L median (range) concentrations, respectively.
Introduction
Synthetic cannabinoids bind to cannabinoid receptors and were developed for studying endocannabinoid pharmacology and potential therapeutic administration; although no drugs are currently available for clinical use to date. [1] [2] [3] [4] [5] Synthetic cannabinoids were introduced as 'legal' cannabis alternatives and became popular worldwide for their psychoactive effects and lack of detectability by routine cannabinoid testing. [6] Synthetic cannabinoids, sold on the Internet, in gas stations and head shops, are labelled 'not for human consumption'. Acute adverse effects from synthetic cannabinoid intake include agitation, anxiety, psychosis/hallucinations, seizures, loss of consciousness, headache, reddened conjunctivae, nausea, vomiting, dry mouth, shortness of breath, tachycardia, chest pain, hypertension, stroke, and in rare cases, acute kidney injury and death. [7] Calls to poison control centres declined since the peak of 6698 in 2011 to 2643 in 2013 [8] ; however, it is unknown if this is a reflection of decreased synthetic cannabinoid intake, physicians' experience in dealing with synthetic cannabinoid cases, or other reasons.
New synthetic cannabinoids constantly emerge in response to legislative efforts worldwide. The Synthetic Drug Abuse Prevention Act of 2012, enacted on 9 July 2012, permanently placed JWH-018, JWH-019, JWH-073, JWH-081, JWH-122, JWH-200, JWH-203, JWH-250, JWH-398, AM694, AM2201, CP 47,497, CP 47,497 C8-homolog, RCS-4, RCS-8 and their analogues under US Drug Enforcement Administration Schedule I regulation. [9] Synthetic cannabinoids also are controlled in Europe, [10] Japan, [11] Australia, [12] and New Zealand [13] and also are banned by the World Anti-Doping Agency (WADA). [14] * Correspondence to: Marilyn A. Huestis, Chemistry and Drug Metabolism, National
Institute on Drug Abuse, NIH, 251 Bayview Blvd. BRC 05A721 Baltimore, MD, 21224, USA. E-mail: mhuestis@intra.nida.nih.gov
Identification of synthetic cannabinoids in biological matrices is critical for documenting intake in clinical and forensic laboratories. Synthetic cannabinoid parent analytes were identified via gas chromatography-mass spectrometry (GC-MS) or liquid chromatography-tandem mass spectrometry (LC-MS/MS) in blood, [15] [16] [17] serum, [18, 19] oral fluid, [20, 21] and hair, [22] [23] [24] while mostly metabolites were found in urine. [12, [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] Although parent synthetic cannabinoids identification in blood, serum, and oral fluid can document acute intoxication and impairment, [17, 36, 37] the window of drug detection in these matrices generally is short. Longer detection may occur after chronic frequent intake, [38] similar to what has been documented following chronic frequent cannabis intake. [39] Urine drug testing is less invasive and offers a wider window of detection, making urine the preferred matrix for workplace drug testing. However, urine requires monitoring metabolites, which are initially unknown for new synthetic cannabinoids. Identifying these targets is critical as new compounds emerge, and reference standards must be synthesized before emerging compounds can be effectively monitored. Moreover, various synthetic cannabinoids can produce common metabolites [25, 28, 30] further complicating urine test interpretation. Synthetic cannabinoids and their metabolites do not cross-react with routine cannabinoid immunoassays, making them desirable for circumventing drug detection efforts. Urine drug testing programmes typically employ immunoassay screening for identifying presumptive positive specimens, and confirmation by GC-MS or LC-MS/MS. [40] Immunoassay screening for synthetic cannabinoids is challenging due to the time required to raise antibodies to metabolites of the constantly new drugs on the market and to develop, validate, and commercialize new assays. Therefore, many laboratories are developing mass spectrometric screening methods for synthetic cannabinoids. [41] [42] [43] [44] [45] These assays target multiple metabolites in a single assay and additional analytes are readily added; however, metabolite standard availability limits the expediency with which this can be accomplished. Many available LC-MS/MS assays are qualitative, but quantifying synthetic cannabinoid urinary metabolites improves results interpretation allowing metabolite concentration correlations with toxicity and adverse outcomes, understanding the drug's pharmacokinetics, and comparing relative concentrations of metabolites to suggest optimal markers.
Limited synthetic cannabinoid urinary metabolites' concentrations are available following self-administration, [12, 28] emergency room visits, [46] and forensic cases. [12, 25, [28] [29] [30] 32] In addition, there is only one report of JWH-018 and JWH-073 metabolites concentrations in US Air Force personnel (n = 49) following random or probable cause drug testing. [31] Most urine concentration data are for only a few analytes following acute intoxications. Knowing synthetic cannabinoid urinary analytes' concentrations in individuals without apparent signs and symptoms of acute intoxication can assist workplace and human performance drug testing programmes in interpreting synthetic cannabinoid test results. To assess personnel readiness and deter illicit drug intake among US service members, the Department of Defense (DOD) established mandatory random and for cause workplace drug testing programmes. Urine specimens, under chain-of-custody, are collected from service members worldwide and shipped at room temperature to any of the six designated DOD forensic toxicology drug testing laboratories for initial immunoassay screening for common drugs of abuse followed by GC-MS confirmation. In conjunction with routine drug testing, the Armed Forces Medical Examiner System conducts prevalence testing by analyzing previously screened negative specimens for emerging drugs of abuse. This enables DOD to assess the severity and impact of illicit drug intake, supporting addition of new drugs into the drug testing panel.
We investigated the suitability of different synthetic cannabinoid urinary markers and their concentrations in US military personnel, with specimens collected in their routine random urine drug testing program. We measured synthetic cannabinoid metabolite concentrations in 777 urine specimens with the most comprehensive published quantitative LC-MS/MS method targeting 53 synthetic cannabinoid analytes consisting of 20 parents and 33 metabolites.
Materials and methods

Reagents and supplies
Standards and deuterated internal standards were purchased from Cayman Chemicals (Ann Arbor, MI, USA). Acetonitrile, ammonium acetate, ethyl acetate, and formic acid were obtained from SigmaAldrich (St Louis, MO, USA) and methanol from Fisher Scientific (Fairlawn, NJ, USA). Solvents utilized in the analysis were HPLC grade or better. Abalone beta-glucuronidase containing 1 500 000 units/g beta-glucuronidase and 150 000 units/g sulfatase was obtained from Campbell Science (Rockton, IL, USA). One mL Isolute supported liquid extraction (SLE+) columns (Biotage, Inc., Charlotte, NC, USA) were utilized in the sample preparation. Ultra Biphenyl HPLC column was purchased from Restek, Inc. (Bellefonte, PA, USA).
Authentic urine specimens
Urine specimens in this study are a subset of 20 017 de-identified, randomly collected US service members' specimens from around the world. Specimens were analyzed for routine drugs of abuse by five DOD forensic toxicology drug-testing laboratories between July 2011 and June 2012. No preservatives were added to the urine per US military protocol. These 20 017 specimens screened negative for cocaine, delta-9-tetrahydrocannabinol (THC), amphetamines, opioids, and phencyclidine (PCP). Presumptive THC positive specimens were not available for our testing because they are confirmed and stored for a minimum of 12 months at DOD testing laboratories, as per chain of custody requirements. Specimens were shipped and stored at room temperature prior to our synthetic cannabinoid immunoassay screening and were subsequently stored at 4°C. Positive specimens were stored at room temperature for 6-152 days (63 mean, 69 median) after collection, and subsequently stored at 4°C for 248-505 (330 mean, 330 median) days before quantitative analysis.
The Randox Drugs of Abuse V immunoassay has four distinct synthetic cannabinoid antibodies: three (SCI, II, and III) primarily target JWH-018 and one (SCIV) targets JWH-250 metabolites. Manufacturer recommended screening cutoff concentrations were: SCI 10, SCII 20, SCIII 5, and SCIV 5 μg/L. Cross-reactivity with synthetic cannabinoids and metabolites included in the qualitative and quantitative LC-MS/MS methods were evaluated and results are summarized in Supplementary Material Table 1 . Limits of detection (LOD) and lower limits of quantification (LLOQ) are listed in Table 1 for the LC-MS/MS qualitative and quantitative assays, respectively. Specimens were screened and confirmed as illustrated in Figure 1 . We included 324 true negative (TN), 5 false negative (FN), 163 false positive (FP), and 285 true positive (TP) specimens based on the Randox immunoassay screen and LC-MS/MS qualitative confirmation to rigorously assess synthetic cannabinoid prevalence and concentrations in our dataset. When we screened these 20 017 specimens with the Randox Drugs of Abuse V synthetic cannabinoid immunoassay, 1 432 were identified as presumptive positive, and 290 confirmed positive via our 29 analyte qualitative LC-MS/MS method. [45] We qualitatively identified 16 synthetic cannabinoid metabolites and 1 parent compound (AM2201). Subsequently, we re-analyzed all 290 qualitatively confirmed positive and 487 negative specimens by our published quantitative LC-MS/MS method [47] targeting 53 synthetic cannabinoid analytes with 0.1-1 μg/L lower limits of quantification (LLOQ) and 50-100 μg/L upper limits of quantification (ULOQs). Specimens with analyte concentrations exceeding ULOQ were diluted with blank urine and re-analyzed. Additional synthetic cannabinoid analytes not included in the qualitative method are listed in Table 1 . All commercially available synthetic cannabinoid standards and internal standards (n = 24) available at the time of method development were included.
Sample preparation and quantitative LC-MS/MS analysis
We analyzed specimens with our published method. [47] Briefly, 200 μL urine specimens were hydrolyzed with β-glucuronidase, and proteins precipitated with acetonitrile prior to SLE. Analytes were eluted with ethyl acetate and dried completely under nitrogen. Specimens were reconstituted in mobile phase (A:B, 50:50, v/v), transferred to autosampler vials, and analyzed on an AB SCIEX 5500 QTRAP® triple quadrupole linear ion trap mass spectrometer. Each specimen was injected twice on an Ultra Biphenyl high performance liquid chromatography (HPLC) column obtaining sensitive positive and negative ionization mode results; two multiple reaction monitoring transitions were examined for all analytes. Total analysis time was 30.9 min (19.5 and 11.4 min for positive and negative mode injections, respectively). Baseline chromatographic separation of 12 isomeric alkyl hydroxy metabolites (Table 1) was unattainable, yielding semi-quantitative results. Inter-day analytical recovery (bias) and imprecision (N = 20) were 88.3-112.2% and 4.3-13.5% coefficient of variation, respectively. Molar ratios of metabolites within each parent synthetic cannabinoid were determined by dividing molar concentration of each metabolite by molar concentration of the most frequently observed metabolite for each parent synthetic cannabinoid. The qualitative LC-MS/MS assay's performance was evaluated by comparing qualitative and quantitative results. Sensitivity, specificity, and efficiency were determined per Ellefsen et al. [48] Sensitivity was calculated as the number of TP specimens divided by the sum of TP and FN specimens multiplied by 100. Specificity was calculated as the number of TN specimens divided by the sum of TN and FP specimens multiplied by 100. Efficiency is equal to the sum of TP and TN specimens divided by the total number of samples (n = 777) multiplied by 100.
Results
Of 777 urine specimens analyzed, 290 contained one or more of 22 synthetic cannabinoid metabolites from 11 parent synthetic cannabinoids. No parent compounds were identified. Mean, median, range of concentrations and number of confirmed specimens for each synthetic cannabinoid metabolite are listed in Table 2 . The following 11 parent synthetic cannabinoids were identified in various combinations (JWH-018, JWH-073, JWH-081, JWH-122, JWH-210, JWH-250, JWH-398, AM2201, MAM2201, RCS-4, Table 1 . Limits of detection (LOD) and lower limits of quantification (LLOQ) for the qualitative [45] and quantitative [47] confirmatory assays for synthetic cannabinoids, respectively 
Analytes isomeric chromatographic separation unattainable; LLOQs determined for a single alkyl hydroxy isomer; analyzed semi-quantitatively.
b
Analytes not chromatographically separated, LOD determined together.
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and UR-144); JWH-018, JWH-073, JWH-122, and AM2201 were the most frequently found (Table 3) 
Discussion
Based on our extensive method validation of the Randox Drugs of Abuse V immunoassay, we documented that two of the four manufacturers' recommended screening cutoffs were inappropriately low, producing a high FP rate for our authentic specimens. We also examined potential FN immunoassay samples and only identified 5 FN with our qualitative LC-MS/MS from 1 069 presumptive negative samples (Figure 1 (Table 1) .
Only eight reports detail synthetic cannabinoid metabolite concentrations in urine, primarily in small datasets of 1-49 individuals, [12, 25, [28] [29] [30] [31] [32] 49] while we present the largest dataset of 290 from 777 randomly collected specimens reporting quantitative synthetic cannabinoid results determined with the most comprehensive LC-MS/MS quantitative method published to date. Our main objectives were determining suitable synthetic cannabinoid urinary targets and concentration ranges in randomly collected specimens under a workplace drug-testing program. Study limitations include limited immunoassay cross-reactivity, potential synthetic cannabinoid metabolites' instabilities, semi-quantitative concentrations for 12 alkyl hydroxy analytes due to unattainable isomeric baseline chromatographic resolution, and lack of commercially available standards precluding quantification of additional urinary synthetic cannabinoid metabolites that were possibly present in our urine specimens. Metabolites for 5 parent synthetic cannabinoids (AM694, HU-210, JWH-203, RCS-8, and XRL11; though the latter shares UR-144 pentanoic acid metabolite with UR-144) included in the quantitative method were unavailable at the time of method validation, which also limited our ability to detect intake.
Most specimens collected from service members are shipped to their designated forensic drug testing laboratories within 24-72 h of collection. These specimens are stored at room temperature during shipment and up to the point of immunoassay screening. Only presumptive positive specimens are stored at 4-7°C; confirmed positive specimens are subsequently stored at -20°C for one year. Specimens from military units located outside of United States (e.g. Europe, Asia, and Middle East) are often stored for weeks to months at room temperature prior to shipment. Therefore, we also assessed the feasibility of detecting synthetic cannabinoids in these urine specimens stored in non-ideal, yet realistic conditions encountered during DOD testing. To our knowledge, there are no published data regarding synthetic cannabinoid analytes' stability in authentic urine specimens. During our quantitative method [47] This short-term parent synthetic cannabinoid instability suggests that instability may be one reason that parent analytes are rarely detected in urine. Because our samples were collected from random routine drug testing and stored at room temperature for prolonged periods of time (mean 62 days, median 64 days, range 6-236 days) prior to LC-MS/MS analysis, it is possible metabolite instability occurred, reducing urinary metabolite concentrations. However, some synthetic cannabinoid metabolites were detected in specimens kept at room temperature for up to 152 days and 505 days at 4°C, suggesting longer urinary analyte stability. Our reported 1.4% positivity rate could be an underestimation due to analyte instability. Urine specimens were collected from July 2011 to June 2012. Of 1 144 seized materials analyzed for synthetic cannabinoids by the United States Army Criminal Investigation Laboratory (USACIL) between November 2011 and June 2012 (report received by personal communication), the top four most prevalent were AM2201, JWH-122, JWH-210, and JWH-018 at 40.3%, 18.1%, 15.1%, and 7.1%, respectively (Figure 2) . JWH-073, JWH-081, JWH-250, MAM2201, RCS-8, UR-144, and XLR-11 were identified in less than 5% of total seizures while JWH-398 was not detected at all. Overall, our trend mirrored USACIL seizures considering AM2201 metabolism yields JWH-018 and JWH-073 metabolites. [28, 30, 50] Although JWH-210 had a higher rate of prevalence in seized materials than our confirmed specimens, the compound's prevalence peaked in August 2011 but steadily declined by January 2012. Most of our specimens were collected between February 2012 and June 2012, which coincided with the period of JWH-210 decline and AM2201 emergence. Thus, JWH-018 metabolites presence in 201 specimens also containing AM2201 metabolites may have originated from AM2201 intake, or a mixture of AM2201 and JWH-018 consumption. Herbal mixtures also may contain one or more synthetic cannabinoids as identified by other laboratories. [51] Therefore, consumption can produce common urinary metabolites from different parent analytes and may impact immunoassay screening rates.
Of 22 metabolites from 11 parent synthetic cannabinoids (JWH-018, JWH-073, JWH-081, JWH-122, JWH-210, JWH-250, JWH-398, AM2201, MAM2201, RCS-4 and UR-144), JWH-018 pentanoic acid had the highest mean (121 μg/L) and median (11.1 μg/L) concentrations. Except for JWH-018 N-hydroxypentyl, median concentrations for other synthetic cannabinoid metabolites were <3 μg/L suggesting lower doses, a greater time between use and urine collection, or greater analyte instability. Many synthetic cannabinoids possess stronger CB 1 receptor binding affinity than THC, [7] requiring lower dosages for achieving desired cannabimimetic effects, and also producing lower urinary metabolite concentrations than observed for THC and metabolites. Brent et al. determined the CB 1 K i for JWH-018 and its 4-hydroxyindole metabolite were 1.2 ± 0.3 nM and 2.7 ± 0.3 nM, respectively, which were 5 6 times lower than THC's K i (15.3 ± 4.5 nM). [52] Moreover, JWH-018 and 4-hydroxindole also are full CB 1 agonists with EC 50 values 6.8 ± 2.5 and 17.0 ± 9.6 nM, respectively, compared with THC's EC 50 of 167.4 ± 85.7 nM.
Synthetic cannabinoid urinary concentration ranges found in our authentic specimens were compared to those reported in the literature. In 2010 ElSohly Laboratories analyzed 33 forensic urine samples, submitted for workplace drug testing programs, and identified JWH-018 pentanoic acid in 17 samples with concentrations between 11.6-27,256 μg/L and JWH-018 N-hydroxypentyl (21.9-5 530 μg/L), but only 35% contained JWH-018 6-hydroxyindole (3.1-35.7 μg/L). [32] No other metabolites were included in their LC-MS/MS assay. In contrast, our JWH-018 pentanoic acid and JWH-018 N-hydroxypentyl concentrations were lower, possibly suggesting lower exposures, longer times since administration or instability during storage for our specimens. Lovett et al. reported synthetic cannabinoid results for 49 urine specimens collected after March 2012 from US Air Force service members suspected of synthetic cannabinoid intake or subject to random drug testing. [31] Specimens contained JWH-018 pentanoic acid (0.7-458 μg/L), JWH-018 N-4-hydroxypentyl (0.1-152 μg/L), JWH-018 N-5-hydroxypentyl (0.4-706 μg/L), JWH-073 butanoic acid (0.8-305.5 μg/L), and JWH-072 propanoic acid (4.7-943.8 μg/L). All specimens contained JWH-018 pentanoic acid and JWH-072 propanoic acid metabolites; 46/49 and 33/49 contained JWH-073 butanoic acid and JWH-018 N-5 hydroxypentyl, respectively. JWH-072 propanoic acid concentrations were 1.6-16.6 times higher than those of JWH-018 pentanoic acid. The authors suggested that JWH-072 propanoic acid was a common biomarker for JWH-018, JWH-073, and AM2201. JWH-072 propanoic acid (or JWH-018 N-propanoic acid) was not commercially available prior to our method validation. Our observed JWH-018 pentanoic concentrations were similar to those reported by Lovett et al. Jang et al. investigated urinary AM2201-and JWH-018 metabolites in individuals arrested for suspected AM2201 (n = 9) and JWH-018 (n = 11) abuse.
[30] AM2201 N-4-hydroxypentyl (5.1-38.2 μg/L) and AM2201 6-hydroxyindole (3.6-24.4 μg/L) were detected in 5 and 6 AM2201-exposed suspects, respectively. However, all specimens (n = 9) also contained JWH-018 pentanoic acid (9.6-401 μg/L) and JWH-018 N-5-hydroxypentyl (3. Converging metabolic pathways for similar synthetic cannabinoids produce common metabolites and most synthetic cannabinoid products contain one or more parent drugs, explaining the presence of multiple synthetic cannabinoid metabolites in individual specimens. Structurally similar synthetic cannabinoids, especially halogenated compounds, produce common metabolites to their non-halogenated analogs. Chimalakonda et al. published human liver microsomal AM2201 and JWH-018 metabolic studies and reported common metabolites (JWH-018 pentanoic acid, JWH-018 N-hydroxypentyl) from both. [50] Oral ingestion of 5 mg pure AM2201 produced JWH-018 pentanoic acid, JWH-018 N-5-hydroxypentyl, JWH-073 butanoic acid, JWH-073 N-4-hydroxybutyl, AM2201 N-4-hydroxypentyl, and AM2201 6-hydroxyindole. [28] JWH-073 butanoic acid also was detected in specimens from individuals who reported JWH-018 intake. [53] We also observed co-occurrence of AM2201 N-hydroxypentyl, JWH-018 pentanoic acid, and JWH-073 butanoic acid in 180 specimens. Either the JWH-018 pentanoic acid and/or JWH-073 butanoic acid were also derived from AM2201 or all three parent analytes were taken in any combination. Similar patterns can be expected for other fluorinated synthetic cannabinoids such as MAM2201 and XLR-11. MAM2201 intake can potentially produce JWH-122 pentanoic acid and JWH-122 N-hydroxypentyl metabolites. For this reason, we cannot assign JWH-122 metabolites from JWH-122 intake alone. We observed 16 positive specimens containing all three metabolites: MAM2201 N-hydroxypentyl (0.1-2.1 μg/L), JWH-122 pentanoic acid (0.5-17.0 μg/L), and JWH-122 N-hydroxypentyl (1.3-250 μg/L) and 87 positive specimens contained only JWH-122 pentanoic acid (0.1-19.1 μg/L). USACIL reported about 20% seized materials contained JWH-122 while MAM2201 was found in less than 5%. In comparison, 5.5% of our specimens contained MAM2201 N-hydroxypentyl and 30% contained JWH-122 metabolites. Others recommended including metabolites unique for the parent compound, i.e., AM2201 4-hydroxypentyl for AM2201 [50] and JWH-018 4-hydroxypentyl for JWH-018. [28] In evaluating the most suitable biomarkers for each synthetic cannabinoid, JWH-018, JWH-073, and JWH-250 carboxy (pentanoic or butanoic acid) metabolites were most frequently identified. Alkyl hydroxy metabolites occurred more frequently for JWH-122, JWH-210, JWH-398, and UR-144. However, median molar ratios between carboxy and alkyl hydroxy metabolites from each parent compound were highly variable (between 0.1 and 3 992%), making it difficult to distinguish optimal biomarkers but lead us to propose targeting carboxy and alkyl hydroxy metabolites. Median molar ratios of JWH-018, JWH-250 and AM2201 hydroxyindole metabolites were lower (<20%) than alkyl hydroxy metabolites and carboxy metabolites, highlighting that hydroxyindole metabolites are minor metabolites. Alkyl hydroxy and carboxy metabolites proved to be effective targets in our study, but other synthetic cannabinoids with different structures could produce different major metabolites. For instance, our hepatocyte studies with AKB48 and STS-135 identified monohydroxylated metabolites at the adamantane ring moiety as more predominant than monohydroxylated metabolites at the indazole or indole alkyl chain. [54, 55] We also observed carboxy formation at the tetramethylcyclopropyl ring as the major metabolite for XLR-11 compared to UR-144 pentanoic acid for UR-144. [56] Adamowicz et al. also detected UR-144 mono-, dihydroxylated, and carboxy urinary metabolites in authentic specimens including metabolites generated from the opened-ring pyrolysis product. [57] These metabolites were unavailable during our method development. Metabolite molar concentration also can be affected by time since last intake, analyte stability, and inter-subject metabolism variability.
Conclusion
We measured concentrations of urinary synthetic cannabinoid metabolites in 290 urine specimens collected from November 2011 to June 2012, the largest dataset of authentic workplace drug testing urine specimens yet published. We quantified concentrations of 22 alkyl hydroxy and carboxy metabolites from 11 parent synthetic cannabinoids (JWH-018, JWH-073, JWH-081, JWH-122, JWH-210, JWH-250, JWH-398, AM2201, MAM2201, RCS-8, and UR-144) by the most comprehensive LC-MS/MS quantitative method to date. The highest synthetic cannabinoid metabolite concentration was 2 434 μg/L for JWH-018 pentanoic acid, although the majority (92.2%) of concentrations were less than 100 μg/L. We determined JWH-018 and AM2201 metabolites were the predominant analytes quantified in our urine specimens, a trend matching seized materials analyzed by USACIL. No parent synthetic cannabinoid was identified in urine, but in many cases, multiple metabolites were present from a single parent compound. Based on in vitro metabolic studies, structurally similar synthetic cannabinoids can produce common metabolites and can make data interpretation challenging. We observed that alkyl hydroxy and carboxy metabolites provided suitable urinary metabolite targets for most synthetic cannabinoids present in our specimens; however, this may vary for newly emerging compounds.
